UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033615
Receipt number R000038319
Scientific Title Prospective multicenter cohort study on the efficacy and safety of benralizumab in the treatment of severe asthma
Date of disclosure of the study information 2018/08/03
Last modified on 2018/08/02 23:31:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective multicenter cohort study on the efficacy and safety of benralizumab in the treatment of severe asthma

Acronym

Prospective multicenter cohort study on the efficacy and safety of benralizumab in the treatment of severe asthma

Scientific Title

Prospective multicenter cohort study on the efficacy and safety of benralizumab in the treatment of severe asthma

Scientific Title:Acronym

Prospective multicenter cohort study on the efficacy and safety of benralizumab in the treatment of severe asthma

Region

Japan


Condition

Condition

Bronchial Asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of efficacy and safety of benralizumab in the treatment of severe asthma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Spirometry

Key secondary outcomes

Astma Control Test(ACT), Asthma Control Questionnaire(ACQ), Asthma Quality of Life Questionnaire(AQLQ), FeNO, Objective opinion, Sputum eosinophil counts, Chest X-ray, Chest CT, Respiratory resistance test, Oral corticosteroid dose, Absence of unexpected visit and hospitalization due to asthma exacerbation, Clinical examination, Sinus CT, Safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Benralizumab is given subcutaneously

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients receiving oral corticosteroid daily
2. Patients with increasing of corticosteroid or needing corticosteroid temporalily at least twice a year due to asthma exacerbation
3. Patients with ACT<25 or ACQ>0

Key exclusion criteria

1. Patients with intention to refuse to participate in this research.
2.Patients with a history of hypersensitivity to this drug and the ingredients of this drug.
3. Patients under 20 years old.
4. Patients who may be pregnant.
5. Patients with breastfeeding
6. Patients deemed ineligible by the attending physicians for various
reasons.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Tachiwada

Organization

University of Occupational and Environmental Health, Japan

Division name

Department of Respiratory Medicine

Zip code


Address

1-1,Iseigaoka,Yahata-nishi-ku, Kitakyushu,Fukuoka,807-8555, Japan

TEL

093-691-7453

Email

kokyu2@mbox.med.uoeh-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Tachiwada

Organization

University of Occupational and Environmental Health, Japan

Division name

Department of Respiratory Medicine

Zip code


Address

1-1,Iseigaoka,Yahata-nishi-ku, Kitakyushu,Fukuoka,807-8555, Japan

TEL

093-691-7453

Homepage URL


Email

kokyu2@mbox.med.uoeh-u.ac.jp


Sponsor or person

Institute

Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan

Institute

Department

Personal name



Funding Source

Organization

Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 08 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2018 Year 07 Month 23 Day

Date of IRB


Anticipated trial start date

2018 Year 08 Month 03 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 08 Month 02 Day

Last modified on

2018 Year 08 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038319


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name